Global Animal Health Market Projection (USD Billion).
THE OPPORTUNITY
Companion Animal Health Is Entering a Metabolic Era
Obesity and metabolic diseases are among the fastest growing health challenges in companion animals – and the market for advanced therapeutics is just beginning.
THE PROBLEM
Existing Treatment Paradigms
Existing Treatment Paradigms Face Significant Real-World Limitations.
- Daily injections or frequent dosing.
- Low owner compliance.
- Unreliable long-term outcomes.
- Limited effective therapeutic options.
OUR SOLUTION
Long-acting
Metabolic Therapeutics Platform
Our proprietary long-acting peptides regulate appetite, glucose and weight with convenient administration every 1–3 months.
- Reduces appetite,
- Lowers blood glucose
- Reduces body weight
- Improves insulin sensitivity
- Tolerance
PLATFORM
A scalableTherapeutic Platform
Existing Treatment Paradigms Face Significant Real-World Limitations.
Developement
strategy
Capital – efficient development with a clear regulatory path.
INVESTMENT
Invest
in a rapidly growing market
See what this business is all about and what you can gain.
Learn about our concept step by step.
MARKET OPORTUNITY
BUSINESS MODEL
OUR TECHNOLOGY
IP STRATEGY
ROAD MAP
GO TO MARKET STRATEGY
MARKET OPORTUNITY
A RAPIDLY GROWING MARKET WITH
LIMITED MODERN SOLUTIONS.
Human Pharm was an introduction to the development of the veterinary market.
- $73B ANIMAL HEALTHCARE MARKET (2025)
- $26B COMPANION ANIMALS SEGMENT (2025)
- $1-3B ADDRESSABLE MARKET METABOLIC THERAPIES
BUSINESS MODEL
B2B2C MODEL
Through veterinary clinics and distributors.
- PREMIUM PRICING
High-value product with strong margins. - RECURRING REVENUE
Repeat dosing every 1-3 months.
OUR TECHNOLOGY
MORE ABOUT OUR TECHNOLOGY
Modern pet medicine
- PEPTIDE SCIENCE
Advanced GLP-1/multi- agonist peptide design. - PROPRIETARY DELIVERY
Depot/implant technology for extended release. - STABILITY
High stability and reliable shelf life. - EASY TO USE
User-friendly pen for veterinarians.
IP STRATEGY
IP / PATENT
- COMPOSITION OF MATTER
Novel peptides and analogs. - FORMULATION
Proprietary long-acting delivery system. - METHOD OF USE
Specific veterinary indications and dosing regimens. - STRONG PROTECTION
Global patent strategy covering key markets.
BUILDING A HIGH-VALUE IP PORTFOLIO AROUND OUR PLATFORM.
ROAD MAP
ROADMAPA
PRE-SEED 0-12 MONTHS
- Formulation development
- In vitro release & stability • Initial in vivo PK • Patent filing
SEED 12-30 MONTHS Proof of concept (dogs/cats)
- Safety & efficacy studies
- Optimize formulation
- Expand patent (PCT)
SERIES A 30-60 MONTHS
Registration studies (EU)
Market authorication
Launch in key markets
BEYOND 60. MONTHS
US market entry
Commercial scale-up
Pipeline expansion
GO TO MARKET STRATEGY
GO TO MARKET STRATEGY
- EUROPE FIRST
Faster regulatory path, pilot launches, first revenues. - GLOBAL VISION
Building a leading position in metabolic therapies for companion animals. - UNITED STATES
Scale through partnerships and direct commercial expansion.
PARTNERSHIP
Why are we a good partner?
We are advancing a differentiated platform positioned at the intersection of significant unmet need and transformative science.
06
See the opportunity?
Invest in this project.
One shot. Months of control.
Better life for pets.
Join us!
